EI Barça will not wait any longer to decide whether or not to cover the long-term withdrawal of Ousmane Dembélé. This Tuesday will make a final decision in this regard. In principle, there is a quorum between Setién and the technical secretariat, commanded by Eric Abidal and Ramon Planes. Everyone agrees to sign, but Barça’s economic straits and the special characteristics of the signing (a player who can only be from LaLiga and who cannot play Champions) condition the decision. What none of the parties involved want is for the decision to take longer. Setién has said that it is “preferable” to sign because another injury would leave Barça in the open. But he has also urged the staff of the technical secretariat to rush into the decision.According to Mundo Deportivo yesterday, Martin Braithwaite, Leganés striker, is another of the strikers that interest. International with Denmark on 39 occasions, the very fast tip joins a list in which Angel, Roger, Budimir, Loren and Lucas Pérez were already. Its clause is 20 million euros. The Leganés, after the sale of En Nesiry, is not willing to release the player, so he would refer to the clause. Braithwaite’s agent, Ali Dursun, is already in Barcelona in case the operation is given a green light. Barça has also contacted Ángel Torres, president of Getafe, to inform him that Ángel is one of the options they handle. The environment of Lucas Pérez (Alavés) sees precisely the Canary as a favorite. But in Barça the secrecy reigns. A week after operating at Dembélé, the name of the replacement is unknown and that allows feeding the rumorology. Budimir, Roger, Loren, Gameiro. Even Munir or Carlos Fernández have been on the radar. But first you have to decide whether or not there is signing. And the blue and grana smoke will be today.
Meanwhile, President Donald Trump pushes importation strategy as solution to cut costs — A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them. Novartis AG has yet to set a price for the gene therapy called Zolgensma, but executives say the drug’s potential to cure spinal muscular atrophy, an inherited disease that typically kills babies before they turn two, justifies a seven-figure price. Gene therapies target diseases that result from a faulty gene by introducing a working version into the body. (Roland, 5/7) Politico: Trump Directs Azar To Work On Florida Drug Import Plan Stat: FDA Approval May Dampen Controversy Over A High-Priced Drug The Food and Drug Administration just added an unexpected twist to a simmering controversy over a rare disease drug that earlier this year briefly became a poster child for high-priced medicines. In a surprise move, the agency approved a medicine from Jacobus Pharmaceuticals, a small, family-run company, for treating a neuromuscular disorder called Lambert-Eaton myasthenic syndrome, or LEMS, for children ages 6 to 17. However, the approval potentially adds unforeseen competition for Catalyst Pharmaceuticals (CPRX), which only last December won an FDA endorsement to market its own treatment for adults. (Silverman, 5/6) This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription. The Wall Street Journal: A $2 Million Drug Is About To Hit The Market President Donald Trump on Monday directed Health and Human Services Secretary Alex Azar to work with Florida Gov. Ron DeSantis on the state’s drug import plan, according to Rep. Matt Gaetz (R-Fla.). Trump and Azar spoke at an Oval Office meeting — attended by DeSantis — that lasted for about 45 minutes Monday afternoon, said Gaetz, who also was at the gathering. (Glorioso, 5/6) ‘A Therapy Is Useless If No One Can Afford It’: $2M Drug Poised To Hit Market Stirs Up Debate Over Cost Of ‘Miracle’ Cures The new treatment that has a potential $2 million price tag can cure spinal muscular atrophy, an inherited disease that typically kills babies before they turn two. But as more gene therapies hit the marketplace, insurers balk at the expense. Meanwhile, the FDA takes an unexpected step to introduce competition into the marketplace for an extremely pricey drug that treats a rare disease.